Introduction
============

The lymphatic vascular system serves key physiological functions: it maintains fluid homeostasis by absorbing water and macromolecules from the interstitium, enables uptake of dietary lipids and vitamins in the intestine, and serves as a trafficking route for immune cells. The lymphatic vasculature consists of a highly branched network of capillaries and ducts that is present in most organs with the exception of the central nervous system and avascular tissues, such as cartilage. Unlike the blood vasculature, the lymphatic vasculature is blind ending ([Fig. 1 A](#fig1){ref-type="fig"}): its small capillaries funnel first into precollecting and larger collecting vessels and then into the thoracic duct or the right lymphatic trunk, which drains lymph into the subclavian veins.

![**Organization of lymphatic vasculature.** (A) The lymphatic vasculature resorbs fluid, macromolecules, and cells from the interstitium. (B) Mechanism of lymph formation in capillaries. Interstitial components penetrate lymphatic capillaries via openings between LECs. The specialized structure of such openings prevents the return of lymph back to the interstitium. Anchoring filaments attach LECs to the ECM and prevent vessel collapse under conditions of increased interstitial pressure (black arrow). (C) Junctional organization of LECs in lymphatic capillaries and collecting vessels. Both "buttons" and "zippers" share a repertoire of adherens and tight junction--associated proteins (e.g., VE-cadherin, zonula occludens-1, occludin, and claudin-5). The main difference between them resides in their organization ([@bib7]). (D) Mechanism of lymph propulsion in collecting vessels. Coordinated opening and closure of lymphatic valves is important for efficient lymph transport. SMCs covering each lymphangion possess intrinsic contractile activity. EC, endothelial cell.](JCB_201012094_RGB_Fig1){#fig1}

Malfunctioning of the lymphatic vasculature results in lymphedema formation and compromises immune function. In the past decade, tremendous progress has been achieved in understanding the mechanisms regulating the morphogenesis of lymphatic vasculature, mainly accomplished by genetically modified mouse models and discovery of mutations responsible for human lymphedema syndromes. In addition, models, such as zebrafish and frog tadpoles, are emerging as powerful tools for studying lymphatic vascular development. In this review, we will summarize the main mechanisms underlying the development of lymphatic vasculature and present an overview of several human diseases that are associated with lymphatic vessel abnormalities.

Mechanisms of lymph transport
=============================

The structure of the different lymphatic vascular compartments, such as capillaries, precollecting, and collecting lymphatic vessels, reflects its dual role in fluid absorption and lymph transport. We will briefly present the main aspects of lymph transport, which have been documented in more detail in recent reviews ([@bib21]; [@bib107]).

Fluid and cell uptake by lymphatic capillaries.
-----------------------------------------------

Lymphatic capillary endothelium has a unique junctional organization ([@bib7]; [@bib21]). Oak leaf--shaped endothelial cells are connected by discontinuous buttonlike junctions. Free overlapping cell edges anchored on each side by these junctions form "flap valves" ([Fig. 1, B and C](#fig1){ref-type="fig"}) through which fluid flows unidirectionally along pressure gradients from the interstitium into the capillary lumen. Actively sprouting lymphatic capillaries have continuous cell--cell junctions, suggesting buttonlike junctions as characteristics of quiescent and functional lymphatic capillary endothelium ([@bib7]). Lymphatic capillaries lack mural cells and connect to the ECM via anchoring filaments ([@bib59]), which prevent the collapse of capillaries upon the increase of interstitial pressure ([Fig. 1 B](#fig1){ref-type="fig"}).

Shear stress generated by transcapillary fluid flow regulates the expression of junctional proteins, up-regulates leukocyte adhesion molecules ICAM-1 and E-selectin, and promotes secretion of chemokine CCL21, mediating dendritic cell migration ([@bib69]). Thus, mechanical stimulation may be important for immune surveillance function of lymphatic vasculature. Dendritic cells first squeeze through pores that punctuate the sparse basement membrane of lymphatic capillaries and, subsequently, reach the lumen through interendothelial flap valves ([Fig. 1 B](#fig1){ref-type="fig"}; [@bib79]). They are then transported toward the draining lymph nodes where they induce immune responses.

Transport of lymph by collecting vessels.
-----------------------------------------

Lymph from lymphatic capillaries is first drained into the precollecting lymphatic vessels that have both lymphatic capillary (oak leaf--shaped lymphatic endothelial cells \[LECs\]) and collecting lymphatic vessel characteristics (valves). Collecting lymphatic vessels consist of a series of functional units, called lymphangions, separated by intraluminal valves, which ensure unidirectional lymph flow ([Fig. 1 D](#fig1){ref-type="fig"}). Collecting vessels are covered with a continuous basement membrane and smooth muscle cells (SMCs). Endothelial cells in collecting vessels are elongated and connected by continuous zipperlike junctions ([Fig. 1 C](#fig1){ref-type="fig"}). Continuous junctions and basement membrane prevent leakage of lymph during its transport.

Lymphatic valves contain two semilunar leaflets, which are covered on both sides by a specialized endothelium anchored to the ECM core ([@bib58]). High lymph pressure upstream of a valve opens the valve and enables lymph flow, whereas reverse flow pushes the leaflets against each other and closes the valve ([Fig. 1 D](#fig1){ref-type="fig"}). Therefore, opening and closing of the valve depend on periodic changes in fluid pressure within collecting vessels. The number of valves per vessel segment varies depending on tissue type, being generally highest in organs with high hydrostatic pressure, e.g., legs in humans ([@bib25]).

Cyclical compression and expansion of lymphatic vessels by surrounding tissues and intrinsic pump forces generated by the spontaneous phasic contraction of SMCs regulate lymph propulsion ([@bib107]). The origin of lymphatic SMCs is unknown, but they contain both smooth and striated muscle contractile proteins and, thus, differ from arteriole SMCs ([@bib71]). Nitric oxide, hormones, and prostanoids control SMC contractions ([@bib107]). In amphibians and reptiles, specialized pulsatile muscular organs or lymph hearts located at the junctions of the lymphatic and venous systems control lymph flow ([@bib50]).

Lymphatic vascular morphogenesis
================================

Lymphatic vascular development requires transdifferentiation of venous endothelial cells toward the lymphatic endothelial phenotype, separation of blood and lymphatic vasculature, sprouting of lymphatic vessels, and lymphatic vascular maturation ([Fig. 2 A](#fig2){ref-type="fig"}). Over 20 genes orchestrate these processes in mice ([Table I](#tbl1){ref-type="table"}**)**, and recently, lymphangiogenesis has also been examined in lower vertebrates, such as fish and frogs.

###### 

Knockout or mutant mouse models and their phenotypes according to stages of lymphatic vascular morphogenesis

  Gene symbol                                           Function                                                         Lymphatic vascular phenotype                                                                                                                                                                                 Expression pattern
  ----------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------
  **LEC differentiation**                                                                                                                                                                                                                                                                                                             
  *Prox1*                                               Transcription factor                                             No LECs (−/−), chylous ascites (+/−); loss of LEC identity, chylous ascites, obesity (*Prox1^f/f^*; Tie2-Cre; [@bib99]; [@bib38]; [@bib48])                                                                  LECs, hepatocytes, lens fiber cells, pancreatic, lung, and intestinal endocrine cells, skeletal muscle, cardiomyocytes
  *Sox18*                                               Transcription factor                                             No LECs(−/−, on C57BL/6J background); abnormal patterning (+/−); edema and chylous ascites (heterozygous *ragged* mutants; [@bib76]; [@bib26])                                                               Endothelial cells
  *Coup-TFII* (*NR2F2*)                                 Transcription factor                                             No LECs (−/−, deletion at or before E9.5); edema, loss of LEC identity, and sprouting (−/−, deletion at later stages; [@bib63]; [@bib90])                                                                    Endothelial cells and SMCs
  **Lymphangiogenesis**                                                                                                                                                                                                                                                                                                               
  Vegf-c--Vegfr-3 pathway                                                                                                                                                                                                                                                                                                             
  *Vegfr3*                                              Receptor tyrosine kinase                                         Hypoplasia, chylous ascites (+/Chy, ENU-induced mutation, loss of tyrosine kinase activity; [@bib52]); lymph sacs formed and defective sprouting (homozygous deletion of ligand-binding domain; [@bib108])   LECs, fenestrated blood vascular endothelial cells, blood vascular endothelial cells in tumors and during early embryogenesis
  *Vegfc*                                               Growth factor, ligand for Vegfr-3                                No sprouting of LECs from veins (−/−); hypoplasia, chylous ascites (+/−; [@bib53])                                                                                                                           Macrophages, SMCs, and subpopulation of mesenchymal cells during development
  *Nrp2*                                                Coreceptor of Vegfr-3 and semaphorins                            Transient capillary hypoplasia, defective sprouting (−/−; [@bib106]; [@bib101])                                                                                                                              Venous and lymphatic endothelial cells
  *Rac1*                                                Rho GTPase                                                       Abnormal migration of LECs from veins (*Rac1^f/f^*; Tie1-Cre; [@bib18])                                                                                                                                      Broad
  *Clp24*                                               Transmembrane protein                                            Lymphangiectasia, ectopic mural cells (*Clp24^−/−^*; *Clp24^−/−^*; *Vegfr3^lacz/+^* and *Clp24^−/−^*; *Vegfr2^lacz/+^*; [@bib84])                                                                            Endothelial cells
  *Tbx1*                                                Transcription factor                                             Hypoplasia and chylous ascites (*Tbx1^f/f^*; Tie2-Cre; [@bib15])                                                                                                                                             Vascular, including LECs
  *Ptpn14* (gene trap)                                  Protein tyrosine phosphatase                                     Hyperplasia of dermal lymphatic vessels in 14% of mutants, paw or periorbital edema ([@bib4])                                                                                                                Broad, including LECs
  Adrenomedullin signaling                                                                                                                                                                                                                                                                                                            
  *Adm* (*adrenomedullin*)                              Peptide vasodilator, ligand for Calcrl                           Hypoplasia of jugular lymph sacs, decreased LEC proliferation, edema (−/−, *Calcrl^LoxP/--^*;Tie2-Cre; [@bib27])                                                                                             Adrenal medulla, vascular SMCs and endothelial cells, cardiomyocytes
  *Ramp2*                                               Coreceptor of Calcrl                                             Hypoplasia of jugular lymph sacs, decreased LEC proliferation, edema (−/−, *Calcrl^LoxP/--^*;Tie2-Cre; [@bib27])                                                                                             Broad, including LECs
  *Calcrl* (*calcitonin receptor-like)*                 G protein--coupled receptor of adrenomedullin                    Hypoplasia of jugular lymph sacs, decreased LEC proliferation, edema (−/−, *Calcrl^LoxP/--^*;Tie2-Cre; [@bib27])                                                                                             Broad, including LECs
  Other                                                                                                                                                                                                                                                                                                                               
  *Vezf*                                                Transcription factor                                             Transient jugular lymphatic hypervascularization (+/−; [@bib57])                                                                                                                                             Broad
  *Tie1*                                                Receptor tyrosine kinase                                         Abnormal lymphatic patterning, dilated and disorganized lymphatic vessels (hypomorphic mice on outbred background; [@bib19])                                                                                 Endothelial and hematopoietic cells
  **Separation of blood and lymphatic vessels**                                                                                                                                                                                                                                                                                       
  Platelet development                                                                                                                                                                                                                                                                                                                
  *Meis1*                                               Transcription factor                                             Blood-filled lymphatic vessels (−/−; [@bib13])                                                                                                                                                               Broad, including developing hematopoietic cells
  Platelet aggregation                                                                                                                                                                                                                                                                                                                
  *Slp76*                                               Adaptor protein                                                  Blood-filled lymphatic vessels, chylous ascites (−/−; [@bib1])                                                                                                                                               Hematopoietic cells
  *Plcg2*                                               Phospholipase C, hydrolysis of phospholipids                     Blood-filled lymphatic vessels, chylous ascites (−/−; [@bib46])                                                                                                                                              Broad
  *Pdpn (podoplanin)*                                   Transmembrane glycoprotein                                       Lymphangiectasia, abnormal lymph transport, lymphedema, blood-filled lymphatic vessels (−/−; [@bib86]; [@bib9]; [@bib94])                                                                                    LECs, keratinocytes, alveolar type II cells, podocytes
  *C1galt1* (encodes T-synthetase)                      Glycosyltransferase, biosynthesis of core-1--derived O-glycans   Blood-filled lymphatic vessels, decreased levels of podoplanin (−/−; [@bib28])                                                                                                                               Endothelial and hematopoietic cells
  *Clec-2*                                              C-type lectin receptor                                           Blood-filled lymphatic vessels (−/−; [@bib9]; [@bib91])                                                                                                                                                      Platelets, peripheral blood neutrophils
  *Syk*                                                 Nonreceptor tyrosine kinase                                      Blood-filled lymphatic vessels, chylous ascites, accumulation of myeloid cells in the dermis (−/−, *Syk*^f/f;^vav-cre; [@bib1]; [@bib9]; [@bib10])                                                           
  Other                                                                                                                                                                                                                                                                                                                               
  *Spred1/Spred2*                                       Cytoplasmic adaptor proteins                                     Blood-filled lymphatic vessels (*Spred1^−/−^;* *Spred2^−/−^;* [@bib93])                                                                                                                                      Broad, including LECs
  **Remodeling, maturation, and valve morphogenesis**                                                                                                                                                                                                                                                                                 
  Tie/PI3-kinase signaling                                                                                                                                                                                                                                                                                                            
  *Akt1*                                                Ser/Thr kinase                                                   Capillary hypoplasia, valve agenesis, dilation, and decreased SMC coverage of small collecting lymphatic vessels (−/−; [@bib109])                                                                            Broad
  *Angpt2*                                              Growth factor, ligand of Tie receptor tyrosine kinases           Hypoplasia, chylous ascites, defective remodeling, and valve agenesis (−/−; [@bib29]; [@bib22])                                                                                                              (Lymph) angiogenenic endothelial cells, hematopoietic cells
  *Pi3kca (mutation* blocking interaction with Ras)     Catalytic p110α isoform of PI3-kinase                            Chylous ascites, hypoplasia, impaired sprouting, and branching of lymphatic capillaries (−/−; [@bib34])                                                                                                      Broad
  *Pik3r1*                                              Regulatory subunits of class IA PI3-kinases                      Chylous ascites, intestinal lymphangiectasia, impaired sprouting, lymphatic, valve agenesis (−/−; [@bib70])                                                                                                  Broad
  **ECM assembly and interactions**                                                                                                                                                                                                                                                                                                   
  *Itga9*                                               Adhesion                                                         Chylothorax, lymphatic valve agenesis (−/−; *Itga9*^f/f^*;* Tie2-Cre and *Itga9*^f/f;^ *Cdh5* (PAC)-CreERT2; [@bib8])                                                                                        BECs and LECs (highest in valves), vascular SMCs
  *Fn1 (removal* of EDA domain)                         ECM component, ligand of Itg-α9                                  Failure of lymphatic valve leaflet elongation (−/−; [@bib8])                                                                                                                                                 Broad, including lymphatic valves
  *Emilin1*                                             E*lastic* microfibril-associated protein                         Hyperplasia and abnormal patterning of lymphatic vessels, reduction of anchoring filaments; impaired lymph drainage, increased lymph leakage (−/−; [@bib20])                                                 Broad, including LECs
  Other                                                                                                                                                                                                                                                                                                                               
  *Aspp1*                                               C*ytoplasmic* adaptor protein                                    Impaired assembly of lymphatic vessels and collecting lymphatic vessel patterning, accumulation of « lymphatic islands » (−/−; [@bib40])                                                                     Endothelial cells
  *Efnb2 (mutation* of PDZ binding site)                Ligand of EphB receptor tyrosine kinases                         Impaired sprouting of capillaries, agenesis of lymphatic valves, ectopic mural cells, chylothorax, retrograde lymph flow (−/−; [@bib65])                                                                     Arterial endothelial cells and SMCs, LECs (highest in the valves)
  *Foxc2*                                               T*ranscription* factor                                           Impaired patterning of capillaries, no collecting lymphatic vessels, agenesis of lymphatic valves, ectopic mural cells, retrograde lymph flow (−/−; [@bib17]; [@bib78]; [@bib73])                            Arterial endothelial cells and SMCs, LECs (highest in the valves)
  *Elk3 (Net)*                                          Transcription factor                                             Lymphangiectasia, chylothorax (−/−; [@bib5])                                                                                                                                                                 Endothelial cells
  *PU.1 Csfr1*                                          Transcription factor receptor for M-CSF1                         Hyperplasia and abnormal patterning of dermal lymphatic vessels (−/−; [@bib33])                                                                                                                              Hematopoietic cells (stage dependent)

ENU, *N*-ethyl-*N*-nitrosourea; PAC, P1-derived artificial chromosome.

![**Main steps of mammalian lymphatic vascular development.** (A) LECs are specified in embryonic veins, from where they sprout toward Vegf-c--producing mesodermal cells and aggregate to form lymph sacs. Further sprouting produces the lymphatic primary plexus composed of capillary-like vessels. Myeloid cells produce cytokines and regulate lymphatic vascular morphogenesis. Primary plexus is further remodeled to form collecting, precollecting, and capillary compartments. Precollecting and collecting lymphatic vessels have intraluminal valves and basement membrane coverage. Collecting lymphatic vessels are surrounded by SMCs (red). (box) Genes important for collecting lymphatic vessel development. (B) LYVE-1 is the earliest known LEC marker. The transcription factor Prox1 is essential for the establishment of LEC identity, and its expression is controlled by Sox18. (C) Signaling via Vegf-c and Vegfr-3 regulates LEC sprouting and proliferation. The role of Vegfr-2--Vegfr-3 heterodimers and participation of Nrp2 in the Vegfr-2--Vegfr-3 complex are not fully understood. (D) Separation of lymphatic and blood vasculature requires platelet aggregation (also see [Table I](#tbl1){ref-type="table"}). Interaction of podoplanin on LECs and CLEC-2 on platelets triggers the Syk-, Slp76-, and PLC-γ2--dependent signaling cascade leading to platelet aggregation. O-glycosylation by T-synthase is important for podoplanin function.](JCB_201012094_RGB_Fig2){#fig2}

Establishment of LEC identity and lymphatic sprouting.
------------------------------------------------------

Lymphatic vessels stem from preexisting blood vessels. Elegant lineage tracing by [@bib89] demonstrated the venous origin of the mammalian lymphatic vasculature as previously proposed ([@bib83]; [@bib49]). The venous origin of LECs has been confirmed in *Xenopus laevis* and zebrafish as shown by real-time imaging in the latter and, therefore, appears to be evolutionary conserved ([@bib74]; [@bib103]; [@bib42]).

In mice, LECs are first specified in the anterior cardinal vein around embryonic day 9.5 (E9.5) when a subset of venous endothelial cells expresses the transcription factor Prox1 and the lymphatic vessel hyaluronan receptor-1 (LYVE-1) in a polar manner ([Fig. 2 B](#fig2){ref-type="fig"}). *Prox1^−/−^* mice do not develop any lymphatic structures because of failed budding and sprouting of LECs ([@bib98]). The transcription factor Sox18 induces Prox1 expression, and *Sox18*^−/−^ mice develop edema caused by blockage of LEC development in the vein in certain genetic backgrounds ([@bib26]). In vitro studies demonstrate SOX18 binding to the *Prox1* promoter and show that PROX1 can confer lymphatic identity to blood endothelial cells (BECs; [@bib44]; [@bib77]; [@bib26]). Thus, Sox18 and Prox1 constitute an essential signaling axis for LEC specification. The nuclear receptor Coup-TFII ([@bib63]; [@bib90]) has an earlier developmental role as a venous identity factor, but it also directly interacts with Prox1 ([@bib60]; [@bib102]) and regulates the expression of LEC-specific genes, such as neuropilin-2 (Nrp2; [@bib63]).

Prox1/LYVE-1--positive cells bud and migrate dorsolaterally from the central veins. They subsequently form the first bona fide lymphatic structures (jugular lymph sacs) in regions where lymphangiogenic growth factor Vegf-c is provided by the lateral mesoderm ([Fig. 2 A](#fig2){ref-type="fig"}; [@bib53]). This process occurs at several positions along the anterior--posterior axis of the early embryo and results in the formation of jugular, medial, and axial lymph sacs, which further give rise to a primary capillary plexus ([@bib83]). Vegf-c is critical in the process: *Vegfc^−/−^* mice lack all lymphatic vasculature, and even *Vegfc^+/−^* displays lymphatic hypoplasia ([@bib53]). The sprouting response of LECs to VEGF-C is mediated by the receptor tyrosine kinase VEGFR-3 and its nonsignaling transmembrane coreceptor Nrp2 ([Fig. 2 C](#fig2){ref-type="fig"}). Nrp2 is highly expressed in lymphatic capillaries and becomes internalized together with VEGFR-3 upon stimulation of LECs with VEGF-C and VEGF-D ([@bib54]). Intriguingly, Nrp2 is important for capillary sprouting but dispensable for the formation of lymph sacs ([@bib106]; [@bib101]). Vegfr-3 is initially expressed also in BECs but becomes mostly restricted to LECs after E10.5. Vegfr-3 signaling depends on interaction with claudinlike protein Clp24 and receptor internalization, a process requiring ephrin-B2 ([@bib84]; [@bib97]). Interestingly, the combined deletion of Vegfr-3 ligands *Vegfc* and *Vegfd* in mice does not phenocopy the inactivation of *Vegfr3*, pointing to a ligand-independent Vegfr-3 function ([@bib36]). Budding of LECs from veins requires Vegfr-3 kinase activity, whereas deletion of the *Vegfr3* ligand-binding domain does not alter lymph sac formation ([Fig. 2, A--C](#fig2){ref-type="fig"}; [@bib108]). Proteolytically processed VEGF-C also interacts with VEGFR-2, which is expressed by lymphatic endothelium. However, activation of Vegfr-2 alone promotes lymphatic vessel enlargement but not sprouting ([@bib100]). VEGF-C induces formation of VEGFR-2/VEGFR-3 heterodimers at angiogenic tip cells, suggesting that heterodimerization of VEGFR-3 with VEGFR-2 may contribute to lymphangiogenic sprouting ([@bib72]). Endothelial-specific loss of Rho GTPase Rac1 leads to an abnormally close association of lymph sacs and cardinal veins, suggesting that it also regulates LEC budding from veins ([@bib18]). Interestingly, postnatal development of lymphatic vessels in organs other than skin is Vegf-c/Vegfr-3 independent, and internal lymphatic capillaries regrow in mice with mutated *Vegfr3* or upon Vegf-c depletion ([@bib52]; [@bib64]; [@bib55]).

In zebrafish, the secreted protein Ccbe1 controls lymphatic sprouting from veins, and its function is conserved, as CCBE1 mutations cause human syndrome presenting with lymphatic dysplasia ([@bib3]; [@bib42]; see Heredity lymphedema syndromes). The venous origin of LECs and conserved function of VEGF-C, VEGFR-3, and CCBE1 ([@bib51], [@bib53]; [@bib74]; [@bib56]; [@bib103]; [@bib3]; [@bib42],[@bib43]) clearly underpin the common origin of the vertebrate lymphatic vasculature. Nevertheless, within this common scheme, there seem to be differences between mammalian and zebrafish LEC behavior: in mice, lymphatic sprouting occurs after veins have formed, whereas zebrafish venous sprouts and lymphatic precursors emerge from the cardinal vein simultaneously ([@bib12]). Half of those venous sprouts connect with intersegmental vessels to form veins, whereas other sprouts disconnect from the vein and migrate toward the horizontal myoseptum region, constituting a pool of future LECs. These cells, called parachordal lymphangioblasts, migrate along arteries either dorsally to form intersegmental lymphatic vessels or ventrally to form the thoracic duct ([@bib12]; [@bib30]). At 5 d after fertilization, a functional lymphatic system has been established in the zebrafish trunk capable of taking up substances from the interstitium and of transporting lymph into the venous system ([@bib56]; [@bib103]). Future studies will have to show whether the requirement for arteries in guiding LEC migration is a zebrafish-specific feature or whether this represents a general scheme among vertebrates: the anatomical proximity of mammalian arteries and lymphatic vessels has often been noted but commonly attributed to high arterial pressure and a need of absorbing extravasated water and proteins near arteries. Using zebrafish, a role for Notch/Dll4 signaling has been demonstrated in guiding LECs along arteries ([@bib30]), and there might be earlier roles for Notch at the level of venous sprouting ([@bib61]). Interestingly, loss of the arterial regulator synectin also compromises the development of zebrafish lymphatics ([@bib39]).

Hematopoietic cells and lymphatic vascular development.
-------------------------------------------------------

In mammals, lymphatic and blood vasculatures are connected only in a few defined locations where lymph is returned back to blood circulation. Platelets are important for keeping both vascular systems apart ([Table I](#tbl1){ref-type="table"}): platelet depletion or defective platelet aggregation leads to abnormal lymphovenous connections and blood-filled lymphatic vessels ([@bib46]; [@bib9]; [@bib13]; [@bib91]; [@bib94]). According to the current model, platelets aggregate at sites of communication between the cardinal vein and lymph sacs and "seal off" lymphatic vessels from the vein ([Fig. 2, A and D](#fig2){ref-type="fig"}). Platelet aggregation is initiated by binding of the O-glycosylated mucoprotein podoplanin expressed on LECs to the Clec-2 receptor on platelets ([@bib9]; [@bib94]). Clec-2 further induces intracellular signaling cascades mediated by spleen tyrosine kinase (Syk), Slp76, and PLC-γ2, which then lead to formation of the blood clot that seals off the vein from the lymph sac ([@bib46]; [@bib9]; [@bib91]).

In addition to platelets, myeloid cells regulate lymphatic vascular morphogenesis. Macrophage-deficient *PU.1^−/−^* and C*sfr1^−/−^* mice exhibit hyperplastic dermal lymphatic capillaries, suggesting that macrophages restrict proliferation of LECs ([@bib33]). Conversely, abnormal accumulation of myeloid cells, producing high levels of cytokines and VEGF-D, induces the formation of dermal lymphaticovenous shunts in *Syk^−/−^* mice ([@bib10]). Similar mechanisms are likely at play in *Angptl4^−/−^* mice, in which excessive macrophage activation by chylomicrons may be responsible for fusion of intestinal blood and lymphatic vessels ([@bib6]; [@bib62]).

Lymphatic vascular remodeling and maturation.
---------------------------------------------

Starting from E15.5, the lymphatic vasculature is reorganized into lymphatic capillaries, precollectors, and collecting lymphatic vessels ([Fig. 2 A](#fig2){ref-type="fig"}). In mice, transient up-regulation of the forkhead transcription factor Foxc2 is the first sign of formation of collecting lymphatic vessels ([@bib73]). Lymphatic valves continue to express high levels of Foxc2 and Prox1 throughout development and in adults. LECs in any given lymphangion decrease the expression of Prox1, Vegfr-3, LYVE-1, and Ccl21, secrete basement membrane components, and acquire SMC coverage ([@bib65]; [@bib73]). In the absence of Foxc2, transition from capillary to collecting lymphatic vessel phenotype and formation of lymphatic valves are arrested ([@bib78]; [@bib73]). FOXC2-bound enhancers in LECs are surrounded by nuclear factor of activated T cells (NFAT) binding sites, and pharmacological inhibition of NFAT activation results in lymphatic patterning defects reminiscent of *Foxc2^−/−^* phenotypes ([@bib73]). This suggests that Foxc2 and NFAT pathways cooperate in establishing collecting lymphatic vessels.

Ephrin--Eph signaling is essential for embryonic angiogenesis, and targeted inactivation in mice of ephrin-B2 or its receptor EphB4 leads to aberrant embryonic blood vessel formation ([@bib2]). Reverse signaling via PDZ interaction sites of ephrin-B2 is also required for the maturation of collecting lymphatic vessels ([@bib65]). In mice, the presence of a mutation in this PDZ interaction site of ephrin-B2 prevents the formation of valves and leads to persistent LYVE-1 expression in presumptive collecting vessels. These mutant mice also display defective sprouting of lymphatic capillaries, which acquire ectopic SMC coverage ([@bib65]).

Integrin α9 and its ligand fibronectin (FN) containing the EIIIA domain (FN-EIIIA) control later steps of lymphatic valve formation ([@bib8]). The integrin α9--β1 complex binds to FN-EIIIA, tenascin, and osteopontin in vitro and regulates the organization of FN-EIIIA microfibrils. Loss of integrin α9 prevents the elongation of valve leaflets, resulting in the formation of ringlike constrictions, which are unable to prevent lymph backflow ([@bib8]). *Fn-EIIIA^−/−^* mice have a similar phenotype, demonstrating that FN-EIIIA is a physiologically relevant integrin α9 ligand ([@bib8]).

The Tie1 and Tie2 endothelial receptor tyrosine kinases are essential for blood vascular remodeling, maturation, and stabilization, and they also control lymphatic vascular development. Mice hypomorphic for Tie1 exhibit LEC hyperplasia and abnormal remodeling of lymph sacs, whereas mice deficient in one of the Tie2 ligands, angiopoietin-2, show defective lymphatic vascular remodeling and lack valves ([@bib29]; [@bib22]; [@bib19]). Tie2 activation induces phosphoinositide (PI) 3-kinase and Akt signaling in vitro, and consistent with these observations, mutations in several PI3-kinase pathway components or loss of *Akt1* leads to lymphatic-remodeling defects ([@bib34]; [@bib70]; [@bib109]). Zebrafish *tie2^−/−^* undergoes normal lymphangiogenesis. However, redundancy with Tie1 needs to be examined ([@bib31]).

Pathological lymphatic vascular morphogenesis
=============================================

Given the importance of lymphatic vessels for normal body functions, it is not surprising that defects of the lymphatic vasculature are implicated in a variety of human pathologies. Roles of lymphatic vessels in tumor metastasis and inflammation have been recently covered in several excellent reviews ([@bib88]; [@bib92]). Here, we will concentrate on the defects of vascular morphogenesis in human lymphedema syndromes and some rare but debilitating diseases in which lymphatic vasculature is suggested to play a central role.

Hereditary lymphedema syndromes.
--------------------------------

Lymphatic vessel dysfunction results in progressive accumulation of protein-rich interstitial fluid and formation of nonpitting localized tissue swelling or lymphedema ([Fig. 3](#fig3){ref-type="fig"}). It is a chronic debilitating condition associated with increased local susceptibility to infections and certain cancers, such as angiosarcoma. Lymphedema can be inherited (primary lymphedema) but is more commonly caused by damage incurred by collecting lymphatic vessels or lymph nodes during cancer surgery or radiation therapy (secondary lymphedema). Pathologies of secondary lymphedema have recently been reviewed ([@bib81], [@bib82]; [@bib92]).

![**Causes of human hereditary lymphedemas.** Lymph transport can be impaired because of a hypoplastic initial lymphatic capillary network, because of abnormal coverage of lymphatic capillaries with basement membrane components and SMCs or because of a lack of or malfunctioning lymphatic valves. Defective lymphatic drainage leads to tissue fibrosis and fat deposition caused by the abnormal local chronic inflammatory response. Genes that are mutated in human hereditary lymphedema are indicated in blue next to the processes to which they are thought to be causally related. Mechanisms of the action of GJC2, PTPN14, and IKBKG are not fully understood.](JCB_201012094_RGB_Fig3){#fig3}

Hereditary lymphedema is a rare genetic disorder, which can develop in utero, neonatally, or more frequently, years or decades after birth ([Fig. 3](#fig3){ref-type="fig"} and [Table II](#tbl2){ref-type="table"}). Missense mutations within the VEGFR-3 tyrosine kinase domain cause Milroy disease, which is characterized by underdeveloped and dysfunctioning cutaneous lymphatic vessels ([@bib51]; [@bib67]). Recently, mutations in the recessive *CCBE1* gene, shown to control lymphatic sprouting in zebrafish ([@bib42]), have been identified in a subset of Hennekam syndrome patients, who develop limb lymphedema, dilated intestinal lymphatic vessels, mental retardation, and facial anomalies ([@bib3]). Intestinal lymphatic capillaries are also reduced in number and abnormally patterned, suggesting that defective lymphatic capillary function is a cause of the syndrome ([@bib3]).

###### 

Main human hereditary lymphedema syndromes

  Name                                                                                                      Inheritance                                  MIM number      Main manifestations                                                                                                                               Mutated gene             Candidate locus
  --------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -----------------
  **Syndromes with lymphedema as a primary manifestation**                                                                                                                                                                                                                                                                                          
  Hereditary lymphedema IA (Milroy disease)                                                                 Autosomal dominant with reduced penetrance   153100          Congenital lymphedema, chylous ascites caused by hypoplasia of lymphatic vessels                                                                  FLT4 (VEGFR-3)           5q35.3
  Hereditary lymphedema IB                                                                                  Autosomal dominant with reduced penetrance   611944          Lymphedema of lower limbs, nature of lymphatic vascular defects is unknown                                                                        Unknown                  6q16.2--q22.1
  Hereditary lymphedema IC                                                                                  Autosomal dominant                           613480          Lymphedema of limbs, age of onset 1--15 yr, nature of lymphatic vascular defects is unknown                                                       GJC2 (connexin47)        1q41--q42
  Hereditary lymphedema II (Meige disease)                                                                  Unknown                                      153200          Puberty onset lymphedema, nature of lymphatic vascular defects is unknown                                                                         Unknown                  Unknown
  **Syndromes with lymphedema as a consistent feature**                                                                                                                                                                                                                                                                                             
  Anhidrotic ectodermal dysplasia with immunodeficiency, osteopetrosis and lymphedema                       X-linked recessive                           300301          Severe infections, osteopetrosis, nature of lymphatic vascular defects is unknown                                                                 IKBKG (Nemo) TER420TRP   Xq28
  Cholestasis-lymphedema syndrome (Aagenaes syndrome)                                                       Autosomal recessive                          214900          Severe neonatal cholestasis, neonatal or childhood onset lymphedema caused by hypoplasia of lymphatic vessels                                     Unknown                  15q1
  Hennekam lymphangiectasia-lymphedema syndrome                                                             Autosomal recessive                          235510          Lymphedema of limbs, intestinal lymphangiectasia, mental retardation, facial anomalies                                                            CCBE1                    18q21.32
  HLT syndrome                                                                                              Autosomal dominant                           607823          Alopecia, ectatic blood vessels, lymphedema, nature of lymphatic vascular defects is unknown                                                      SOX18                    20q13.33
  Lymphedema, microcephaly, chorioretinopathy syndrome                                                      Autosomal dominant                           152950          Congenital microcephaly and lymphedema, nature of lymphatic vascular defects is unknown                                                           Unknown                  Unknown
  Lymphedema-choanal atresia syndrome                                                                       Autosomal recessive                          608911          Blockage of nasal passage (choana), lymphedema of lower legs at 4--5 yr, nature of lymphatic vascular defects is unknown                          PTPN14                   1q32--q41
  Lymphedema--distichiasis syndrome, yellow nail syndrome                                                   Autosomal dominant                           153400/153300   Late onset leg lymphedema and metaplasia of Meibomian glands (distichiasis), impaired lymphatic drainage caused by incompetent lymphatic valves   FOXC2                    6q24.3
  Persistence of mullerian derivatives with lymphangiectasia and postaxial polydactyly (Urioste syndrome)   Autosomal recessive?                         235255          Intestinal and pulmonary lymphangiectasia, protein-losing entheropathy, polydactyly, and mullerian duct remnants                                  Unknown                  Unknown
  Pulmonary congenital lymphangiectasia                                                                     Unknown                                      265300          Congenital pulmonary lymphangiectasia, subcutaneous edema, nonimmune hydrops, chylothorax                                                         Unknown                  Unknown

References can be found under the corresponding Online Mendelian Inheritance of Man (MIM) entry.

Loss-of-function mutations in *FOXC2* cause lymphedema--distichiasis syndrome (LD), which is characterized by late onset lymphedema and a double row of eyelashes (distichiasis; [@bib23]). Gain-of-function mutations in *FOXC2* occur in patients with lymphedema, but the association of these mutations with distichiasis awaits further investigation ([@bib95]). Lymphatic vessel density is normal or increased in LD patients; however, lymphatic transport is inefficient because of lymph reflux, likely caused by incompetent lymphatic valves. LD patients also have venous reflux, suggesting a common mechanism for the morphogenesis of venous and lymphatic valves ([@bib11]; [@bib66])

Dominant-negative mutations in *SOX18* occur in hypotrichosis--lymphedema--telangiectasia syndrome (HLT) characterized by sparse hair, swelling of legs, and dilation of small blood vessels. Based on phenotypic similarities with mice producing a dominant-negative form of Sox18, HLT patients likely have lymphatic capillary hypoplasia ([@bib47]; [@bib26]). Novel causes of hereditary lymphedema include mutations in gap junction protein GJC2 and protein tyrosine phosphatase PTPN14 ([@bib4]; [@bib24]). GJC2 is highly expressed by oligodendrocytes, and recessive loss-of-function mutations in *GJC2* cause hereditary Pelizaeus--Merzbacher-like disease, which is characterized by central nervous system demyelination. Given the dominant character of *GJC2* mutations in lymphedema, mutant proteins might exert a dominant-negative effect either on remaining wild-type GJC2 molecules or other connexins. A subset of *Ptpn14*-deficient mice has hyperplastic lymphatic vasculature, and a role for PTPN14 in restricting Vegfr-3 activation has been proposed ([@bib4]).

Lymphangioleiomyomatosis (LAM).
-------------------------------

LAM is a rare lung disease affecting women of childbearing age characterized by the proliferation of smooth muscle--like cells and lymphatic vessels as well as the formation of pulmonary cysts. LAM can also occur in the axial lymphatics and is associated with a benign kidney tumor angiomyolipoma ([@bib87]). The origin of the SMCs in LAM lesions is unknown, but they respond to estrogen and express multiple chemokine receptors and lymphangiogenic growth factors VEGF-C and VEGF-D, which may explain the highly metastatic behavior of LAM cells and their close association with lymphatic vessels ([@bib75]; [@bib105]). LAM is a benign neoplasm. However, LAM cells frequently disseminate through lymphatic vessels to distant sites, where they may block lymphatic function, causing accumulation of lymph in the chest and abdominal cavity and lymphedema. The cystic destruction of the lung parenchyma over time impairs lung function, which is ultimately only rescuable through lung transplantation ([@bib87]).

The kinase mammalian target of rapamycin (mTOR) plays a central role in integrating growth factor--activated signaling. Its abnormal activation is a likely cause of LAM, as patients with germline mutations of mTOR repressors tuberosis sclerosis complex-1 and -2 (TSC1 and TSC2) genes develop the disease. Somatic biallelic loss of *TSC2* occurs in sporadic LAM cases ([@bib14]; [@bib85]). In line with these findings, encouraging results were observed in patients treated with mTOR inhibitors ([@bib32]). Given the close association of LAM cells with lymphatic vessels and the lymphatic pattern of dissemination, combining the blockage of mTOR with antilymphangiogenic therapy seems to be a reasonable further step in developing better treatment for this disease.

Gorham disease (GD).
--------------------

GD is a rare disease of unknown etiology characterized by bone resorption and local vascular proliferation. The disease is frequently complicated by systemic dysfunction of lymphatic vessels, such as chylothorax and chylous ascites ([@bib80]). Endothelial cells in the lesions are likely of LEC origin, as they express LEC markers LYVE-1 and podoplanin, and VEGFR-3 is increased in 50% of vessels ([@bib35]). Nonendothelial cells from GD lesions resemble immature osteoclasts; they secrete cytokines and angiogenic factors, are highly invasive, and may, thus, contribute to disease progression ([@bib16]). Moreover, GD osteoclast precursors show increased sensitivity to humoral factors, promoting osteoclast formation and bone resorption ([@bib41]). Overall, the clinical picture points to an intriguing link between LEC proliferation and activation of osteoclast-mediated bone resorption; however, at present, no candidate genes for GD have been identified.

Kaposi sarcoma (KS): a case of mixed identity.
----------------------------------------------

KS is a tumor caused by human herpes virus 8 (HHV8 or KS-associated herpes virus \[KSHV\]). The lesions are composed of spindle-shaped tumor cells, leaky and highly proliferative vessels, extravasated red blood cells, and inflammatory infiltrate ([@bib68]). KS cells express markers of both blood (CD34 and CXCR4) and LEC lineages (VEGFR-3, LYVE-1, and podoplanin). Interestingly, KSHV infection of BECs shifts the transcriptional profile toward a LEC phenotype, whereas KSHV infection of LECs induces transcriptional reprogramming toward a more BEC-like phenotype ([@bib45]; [@bib96]).

The major latency viral transcripts expressed in KS cells include the latency-associated nuclear antigen, viral cyclin, vFLIP, viral-encoded micro-RNAs, and kaposin-A and -B. These transcripts are important for KHSV-induced cell proliferation, production of proangiogenic and inflammatory cytokines, and unrestricted replicative potential ([@bib68]). Notably, some of these molecules control endothelial cell differentiation in vitro: four KS micro-RNAs target the transcription factor MAF and contribute to reprogramming of the LEC to BEC phenotype, whereas kaposin-B stabilizes PROX1 mRNA, which has a key role in lymphatic endothelial identity ([@bib37]; [@bib104]). Overall, these data provide an intriguing example of virus-mediated change of the endothelial cell differentiation program.

Open questions and outlook
==========================

Impressive progress has been achieved in the past decade in the field of lymphatic vascular biology, but many questions remain unresolved. Development of novel imaging techniques and analysis of signaling pathways in situ will certainly provide additional insights into the mechanisms of lymphangiogenesis. Considerable phenotypic plasticity of endothelial cells is now obvious; however, the genetic and epigenetic mechanisms of LEC differentiation are far from being fully understood. Contributions of other cell types in regulating lymphatic development and function need to be addressed under physiological and pathological conditions. Finally, organ- and disease-specific features and responses of lymphatic endothelium have not been studied in detail, although this knowledge may have a critical impact on developing better treatments for human pathologies, including lymphedema, cancer, and inflammation.

We thank Caroline Heckman and Jeremiah Bernier-Latmani for discussions, and we apologize to colleagues whose work could not be cited because of space limitations.

The authors' work is supported by the Swiss National Science Foundation (grant PPP0033-114898), the Medic, Telethon, and Emma Muschamp Foundations, the National Center of Competence in Research Molecular Oncology, the Oncosuisse, the Swiss Cancer League, the Association for International Cancer Research, the Royal Netherlands Academy of Arts and Sciences, and the Wageningen University and Research Centre.

Abbreviations used in this paper:BECblood endothelial cellFNfibronectinGDGorham diseaseHLThypotrichosis--lymphedema--telangiectasia syndromeKSKaposi sarcomaKSHVKS-associated herpes virusLAMlymphangioleiomyomatosisLEClymphatic endothelial cellLDlymphedema--distichiasis syndromemTORmammalian target of rapamycinNFATnuclear factor of activated T cellsPIphosphoinositideSMCsmooth muscle cellSykspleen tyrosine kinase
